Emerging Markets Provide Leapfrog Opportunity For Covidien-Medtronic
This article was originally published in PharmAsia News
PharmAsia News takes a look at the Medtronic-Covidien deal and the role of emerging markets. Medtronic CEO Omar Ishrak thinks well ahead of the industry and talk is percolating that the play is about leapfrog technology in emerging markets for medical equipment - much like mobile phones allowed countries without decades of telecom infrastructure to expand quickly at lower costs.
You may also be interested in...
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.
India’s top regulatory agencies are weighing up the findings from a study it had commissioned that looks at the clinical benefits of heart stents, with the possible aim of using the results to back the use of cheaper, locally-produced devices.